Posted 31 August 2012
Johnson and Johnson will pay $181 million to settle a lawsuit about how it marketed an antipsychotic drug, but the company denies any
wrongdoing, according to a PMLive report.
The suit claims the drug, Risperdal, was promoted for uses not approved by the U.S. Food and Drug Administration and also made false claims about its effects. The payment will be distributed to 36 states and the District of Columbia, the report said.
This is the latest round of problems J&J has had with Risperdal. The report lists fines and settlements from cases in Arkansas ($1.1 billion), Texas ($158 million), and with the U.S Department of Justice ($600 million).
The company said the settlement was "not an admission of wrongdoing or violation of any law or regulation" and instead was to resolve concerns of attorney generals and to avoid unnecessary expense and a lengthy legal battle, according to the report.